UAB 19113: A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients with MDS and AML

Grant

Date/time Interval

  • November 5, 2020 - November 4, 2024
  • Total Award Amount

  • 707600.00
  • Direct Costs

  • 520294.00
  • Sponsor Award Id

  • Contributor

  • Kimo Bachiashvili   Investigator  
  • Luciano Costa M.D., Ph.D.   Investigator  
  • Omer Jamy   Investigator  
  • Pankit Vachhani   Principal Investigator  
  • Ravi Bhatia M.D.   Investigator